Table 2.
Outcome comparison between groups.
| Outcomes | MELD1 (n = 1342) | MELD2 (n = 1341) | MELD3 (n = 1349) | MELD4 (n = 1341) | χ2 | p |
|---|---|---|---|---|---|---|
| ACM, n (%) | 55 (4.1) | 66 (4.9) | 65 (4.8) | 87 (6.5) | 8.452 | 0.038 |
| CM, n (%) | 42 (3.1) | 51 (3.8) | 53 (3.9) | 72 (5.4) | 9.175 | 0.027 |
| MACCE, n (%) | 172 (12.8) | 189 (14.1) | 194 (14.4) | 209 (15.6) | 4.262 | 0.234 |
| MACE, n (%) | 159 (11.8) | 172 (12.8) | 178 (13.2) | 185 (13.8) | 2.386 | 0.496 |
| Heart failure, n (%) | 44 (3.3) | 43 (3.2) | 38 (2.8) | 38 (2.8) | 0.808 | 0.848 |
| Bleeding events, n (%) | 41 (3.1) | 29 (2.2) | 43 (3.2) | 46 (3.4) | 4.288 | 0.232 |
| Readmission, n (%) | 175 (13.0) | 184 (13.7) | 182 (13.5) | 196 (14.6) | 1.493 | 0.684 |
| TVR, n (%) | 67 (5.0) | 67 (5.0) | 82 (6.1) | 66 (4.9) | 2.505 | 0.474 |
MELD, model for end-stage liver disease; ACM, all-cause mortality; CM, cardiac mortality; MACE, major adverse cardiovascular event; MACCE, major adverse cardiovascular and cerebrovascular event; TVR, target vessel reconstruction.